Fishawack Health (Fishawack) is a leading global commercialization partner for the modern life sciences era. The company’s three core operating units—Commercial, Consulting, and Medical Communications—can be leveraged individually but are designed for dynamic collaboration, with expert teams intentionally and uniquely assembled for each project.
By bringing together best-in-class capabilities from around the world, Fishawack empowers its clients—global pharmaceutical, medical device manufacturers, and emerging biotech and healthcare companies—to navigate the most complex of ecosystems while embarking on a faster, more efficient path to developing, launching, and growing their brands and portfolios.
Fishawack has become one of the largest healthcare communications organizations in the world with 14 offices in Europe and the US, and a highly skilled workforce of 850 employees. The organization serves more than 100 customers across 300 different drug compounds, including all of the top 20 global pharmaceutical companies and a range of innovative biotech and medical device companies.
Continuing its growth acquisition strategy, Fishawack recently acquired The Hive Health Group, a strategically led healthcare marketing and scientific communications business based in London and New York.
The Hive Health Group is made up of 2 brands, Hive Health and Pollen Health, which partner with clients across the life science industry. The resulting partnership further bolsters Fishawack’s client roster.
The acquisition follows Fishawack’s recent purchase of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the U.S. Skysis expertise bolsters Fishawack’s consulting capabilities. The company brings with it the ability to connect interdependencies across HCP, payer, channel, and patient stakeholders.
Takeaway: Fishawack Health is leveraging its new investor Bridgepoint’s support of its growth strategy